Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a disposable system attached to the patient's back via biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis and report generation. The company was founded in 2004 and is based in Isfiya, Israel.
IPO Year: 2015
Exchange: NASDAQ
Website: check-cap.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2021 | $4.00 → $3.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $3.00 from $4.00 previously
Dawson James downgraded Check-Cap from Buy to Neutral and set a new price target of $2.00
HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $4.00 from $1.50 previously
Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Trusted to Create Shareholder Value or Oversee Management! Company Leadership Lacks Any Credible Strategic Plan and Has Made Numerous Reckless Acquisitions While Rewarding Themselves with Excessive Compensation for Repeated Failures Apollo's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting Sends Le
Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Trusted to Create Shareholder Value or Oversee Management! Company Leadership Lacks Any Credible Strategic Plan and Has Made Numerous Reckless Acquisitions While Rewarding Themselves with Excessive Compensation for Repeated Failures Apollo's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting Sends Let
Proposed business combination to create a North American technology company with an AI-driven fintech marketplace. Combined company to apply for listing on Nasdaq and TSX TORONTO, March 25, 2024 /PRNewswire/ -- Nobul AI Corp. ("Nobul") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Business Combination Agreement (the "Business Combination Agreement") under which the shareholders of Nobul will become the majority holders of the combined company. If completed, the business combination will create a public company headquartered in Toronto, Canada and focused on an AI-driven fintech marketplace as well as buying and AI-ena
TORONTO, Dec. 22, 2023 /PRNewswire/ - Symetryx Corporation ("Symetryx"), a Canadian venture company, is pleased to announce that the shareholders of Check-Cap Ltd. (NASDAQ:CHEK) voted overwhelmingly to elect all the director nominees proposed by Symetryx at the Annual General Meeting held on December 18th 2023. The CHEK shareholders, amongst other matters, voted overwhelmingly not to approve the proposed merger with Keystone Dental. Barry R. Shiff, President of Symetryx, commented, "as one of the largest shareholders of Check-Cap, we are grateful for the support we received from our fellow shareholders. Despite facing many challenges, we prevailed. We believe, as many of our fellow shareho
ISFIYA, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Check-Cap, Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK) today issued the following letter from its Board of Directors to its shareholders and to the investment community: Dear Check-Cap Shareholders, The Board of Directors wishes to inform shareholders and the broader investment community that on December 12, 2023, Check-Cap won a motion filed by Symetryx in Israeli court, with the Court rejecting all claims raised by Symetryx, including those purportedly related to a personal interest or conflict of interest of Check Cap's Board of Directors in the Keystone business combination. With this letter, Check-Cap is correcting the false a
SYMETRYX RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER SYMETRYX RECOMMENDS VOTING FOR THEIR QUALIFIED INDEPENDENT BOARD NOMINEES TIME IS SHORT - THE VOTE DEADLINE IS 11:59 pm EST THURSDAY DECEMBER 14th 2023 - SHAREHOLDERS MAY VOTE OR CHANGE A PREVIOUSLY CAST VOTE UNTIL THAT TIME TORONTO, Dec. 13, 2023 /PRNewswire/ - Further to its news release of November 28, 2023, Symetryx continues to urge its fellow Check-Cap Ltd. ("Check-Cap") (NASDAQ:CHEK) shareholders to VOTE AGAINST the Keystone Dental and FOR the Symetryx slate of highly qualified and independent director nominees. See Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting (newswire.
TORONTO, Dec. 8, 2023 /PRNewswire/ - Further to its news release of November 28, 2023, Symetryx continues to urge its fellow Check-Cap Ltd. ("Check-Cap") (NASDAQ:CHEK) shareholders to VOTE AGAINST the Keystone Dental and FOR the Symetryx slate of highly qualified and independent director nominees. See Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting (newswire.ca) Keystone Dental ("Keystone") reported on November 22nd through a 6K filling with the Securities and Exchange Commission (the "SEC") under Check-Cap's SEC filing page, the following: On November 6, 2023, Keystone received a deficiency letter from the U.S. Food and Drug Administration
ISS recommends voting FOR the re-election of Check-Cap's director nominees and AGAINST the election of the director nominees put forth by Symetryx ISS recommends approval of the authorization of Check-Cap's board of directors to effect a reverse share split ISFIYA, Israel, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK) today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended that Check-Cap shareholders vote FOR approval of the business combination agreement with Keystone Dental Holdings, Inc. ("Keystone") at the upcoming Annual General Meeting of Shareholders ("AGM"), sc
TORONTO, Dec. 5, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") once again encourages our fellow shareholders of Check-Cap Ltd. ("Check-Cap") (NASDAQ:CHEK) to review the news release issued by Yoav Kimchy, PhD, the Founder and former Chief Technology Officer, and shareholder, of Check-Cap, who has stated in an open letter to his fellow shareholders that the value of the Intellectual Property of Check-Cap was, in essence, disregarded and assigned no monetary value when valuing the Keystone Dental transaction. See Check-Cap Founder and Former Chief Technology Officer Issues an Open Letter to His Fellow Shareholders (newsfilecorp.com) Further to its news release of November 28, 2
Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO, Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ:CHEK) shares, today issued the following open letter to shareholders. In the letter Symetryx cites, among other items, its serious concerns and reason for voting AGAINST the proposed transaction with Keystone Dental. Symetryx discusses its concerns around the actions of the Board in its evaluation
SC 13D/A - Check-Cap Ltd (0001610590) (Subject)
SC 13D - Check-Cap Ltd (0001610590) (Subject)
SC 13D/A - Check-Cap Ltd (0001610590) (Subject)
SC 13D/A - Check-Cap Ltd (0001610590) (Subject)
SC 13D/A - Check-Cap Ltd (0001610590) (Subject)
SC 13D - Check-Cap Ltd (0001610590) (Subject)
SC 13G - Check-Cap Ltd (0001610590) (Subject)
SC 13G/A - Check-Cap Ltd (0001610590) (Subject)
SC 13G - Check-Cap Ltd (0001610590) (Subject)
IRVINE, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Osteon Medical, a subsidiary of Keystone Dental Holdings ("Keystone Dental" or the "Company"), today announced the United States Patent and Trademark Office (USPTO) has granted the Company a patent for its innovative Nexus IOS solution. The Nexus iOS Scan Gauge technology allows implant dentists to perform direct full-arch implant scans using an Intraoral Scanner (IOS) with predictable and passive fitting prosthetic outcomes. This technology replaces the traditionally manual impression-taking process through a faster, cost-effective, and accessible workflow. The Nexus iOS Scan Gauge technology is now the only patented elongated body scan
Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, arches and other tooth replacement solutions Keystone 2022 revenues exceeded $60 million The combined company will trade on the NASDAQ with the ticker "KSD" Investor conference call and webcast scheduled for 8:30 a.m. ET on Thursday, August 17th IRVINE, Calif. and BURLINGTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings, Inc. ("Keystone Dental") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Busin
NT 20-F - Check-Cap Ltd (0001610590) (Filer)
6-K - Check-Cap Ltd (0001610590) (Filer)
6-K - Check-Cap Ltd (0001610590) (Filer)
6-K - Check-Cap Ltd (0001610590) (Filer)
6-K - Check-Cap Ltd (0001610590) (Filer)
6-K - Check-Cap Ltd (0001610590) (Filer)
6-K - Check-Cap Ltd (0001610590) (Filer)
6-K - Check-Cap Ltd (0001610590) (Filer)
20-F - Check-Cap Ltd (0001610590) (Filer)
NT 20-F - Check-Cap Ltd (0001610590) (Filer)
Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO, Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ:CHEK) shares, today issued the following open letter to shareholders. In the letter Symetryx cites, among other items, its serious concerns and reason for voting AGAINST the proposed transaction with Keystone Dental. Symetryx discusses its concerns around the actions of the Board in its evaluation
ISFIYA, Israel, Sept. 1, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs. Dr. Brenner-Lavie will be responsible for leading the Company's overall clinical strategy and implementation as well as driving the Company's clinical direction, including innovation. "Dr. Brenner-Lavie has a proven track record of clinical strategy dev